Correlation Between Syndax Pharmaceuticals and Achilles Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Syndax Pharmaceuticals and Achilles Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Syndax Pharmaceuticals and Achilles Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Syndax Pharmaceuticals and Achilles Therapeutics PLC, you can compare the effects of market volatilities on Syndax Pharmaceuticals and Achilles Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Syndax Pharmaceuticals with a short position of Achilles Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Syndax Pharmaceuticals and Achilles Therapeutics.

Diversification Opportunities for Syndax Pharmaceuticals and Achilles Therapeutics

0.27
  Correlation Coefficient

Modest diversification

The 3 months correlation between Syndax and Achilles is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and Achilles Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Achilles Therapeutics PLC and Syndax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Syndax Pharmaceuticals are associated (or correlated) with Achilles Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Achilles Therapeutics PLC has no effect on the direction of Syndax Pharmaceuticals i.e., Syndax Pharmaceuticals and Achilles Therapeutics go up and down completely randomly.

Pair Corralation between Syndax Pharmaceuticals and Achilles Therapeutics

Given the investment horizon of 90 days Syndax Pharmaceuticals is expected to generate 2.4 times less return on investment than Achilles Therapeutics. In addition to that, Syndax Pharmaceuticals is 1.07 times more volatile than Achilles Therapeutics PLC. It trades about 0.06 of its total potential returns per unit of risk. Achilles Therapeutics PLC is currently generating about 0.15 per unit of volatility. If you would invest  118.00  in Achilles Therapeutics PLC on December 28, 2024 and sell it today you would earn a total of  30.00  from holding Achilles Therapeutics PLC or generate 25.42% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy93.33%
ValuesDaily Returns

Syndax Pharmaceuticals  vs.  Achilles Therapeutics PLC

 Performance 
       Timeline  
Syndax Pharmaceuticals 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Syndax Pharmaceuticals are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain fundamental indicators, Syndax Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.
Achilles Therapeutics PLC 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Syndax Pharmaceuticals and Achilles Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Syndax Pharmaceuticals and Achilles Therapeutics

The main advantage of trading using opposite Syndax Pharmaceuticals and Achilles Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Syndax Pharmaceuticals position performs unexpectedly, Achilles Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will offset losses from the drop in Achilles Therapeutics' long position.
The idea behind Syndax Pharmaceuticals and Achilles Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum